nodes	percent_of_prediction	percent_of_DWPC	metapath
Orlistat—FASN—breast cancer	0.295	0.618	CbGaD
Orlistat—PLA2G4A—breast cancer	0.15	0.315	CbGaD
Orlistat—PLA2G4A—Epirubicin—breast cancer	0.0902	0.404	CbGbCtD
Orlistat—CYP3A4—breast cancer	0.032	0.0671	CbGaD
Orlistat—CYP3A4—Exemestane—breast cancer	0.0177	0.0792	CbGbCtD
Orlistat—CYP3A4—Letrozole—breast cancer	0.015	0.0673	CbGbCtD
Orlistat—CYP3A4—Anastrozole—breast cancer	0.0134	0.06	CbGbCtD
Orlistat—CYP3A4—Toremifene—breast cancer	0.0123	0.0549	CbGbCtD
Orlistat—CYP3A4—Fulvestrant—breast cancer	0.0114	0.051	CbGbCtD
Orlistat—CYP3A4—Thiotepa—breast cancer	0.0102	0.0455	CbGbCtD
Orlistat—CYP3A4—Ixabepilone—breast cancer	0.0093	0.0416	CbGbCtD
Orlistat—CYP3A4—Lapatinib—breast cancer	0.00895	0.04	CbGbCtD
Orlistat—CYP3A4—Raloxifene—breast cancer	0.00678	0.0303	CbGbCtD
Orlistat—CYP3A4—Vinorelbine—breast cancer	0.00496	0.0222	CbGbCtD
Orlistat—CYP3A4—Tamoxifen—breast cancer	0.00448	0.0201	CbGbCtD
Orlistat—CYP3A4—Mitoxantrone—breast cancer	0.00437	0.0196	CbGbCtD
Orlistat—DAGLB—mammary gland—breast cancer	0.00374	0.0576	CbGeAlD
Orlistat—CYP3A4—Paclitaxel—breast cancer	0.00349	0.0156	CbGbCtD
Orlistat—CYP3A4—Irinotecan—breast cancer	0.00344	0.0154	CbGbCtD
Orlistat—LIPF—pituitary gland—breast cancer	0.00338	0.0521	CbGeAlD
Orlistat—CYP3A4—Vinblastine—breast cancer	0.00306	0.0137	CbGbCtD
Orlistat—ABHD12—mammary gland—breast cancer	0.00265	0.0409	CbGeAlD
Orlistat—CYP3A4—Docetaxel—breast cancer	0.00252	0.0113	CbGbCtD
Orlistat—PLA2G7—nipple—breast cancer	0.0025	0.0385	CbGeAlD
Orlistat—ABHD16A—nipple—breast cancer	0.00234	0.0361	CbGeAlD
Orlistat—FASN—mammary gland—breast cancer	0.00223	0.0343	CbGeAlD
Orlistat—ABHD12—nipple—breast cancer	0.00219	0.0338	CbGeAlD
Orlistat—CYP3A4—Doxorubicin—breast cancer	0.00188	0.00841	CbGbCtD
Orlistat—FASN—nipple—breast cancer	0.00184	0.0284	CbGeAlD
Orlistat—DAGLB—adipose tissue—breast cancer	0.00168	0.0259	CbGeAlD
Orlistat—DAGLB—adrenal gland—breast cancer	0.00151	0.0232	CbGeAlD
Orlistat—PLA2G7—endometrium—breast cancer	0.00151	0.0232	CbGeAlD
Orlistat—ABHD16A—endometrium—breast cancer	0.00141	0.0218	CbGeAlD
Orlistat—DAGLB—female gonad—breast cancer	0.00141	0.0217	CbGeAlD
Orlistat—PLA2G7—pituitary gland—breast cancer	0.00136	0.021	CbGeAlD
Orlistat—PLA2G7—adipose tissue—breast cancer	0.00136	0.0209	CbGeAlD
Orlistat—ABHD12—endometrium—breast cancer	0.00133	0.0204	CbGeAlD
Orlistat—ABHD16A—pituitary gland—breast cancer	0.00128	0.0197	CbGeAlD
Orlistat—ABHD16A—adipose tissue—breast cancer	0.00127	0.0196	CbGeAlD
Orlistat—PLA2G7—adrenal gland—breast cancer	0.00122	0.0188	CbGeAlD
Orlistat—PNLIP—pituitary gland—breast cancer	0.0012	0.0185	CbGeAlD
Orlistat—ABHD12—pituitary gland—breast cancer	0.0012	0.0185	CbGeAlD
Orlistat—ABHD12—adipose tissue—breast cancer	0.00119	0.0184	CbGeAlD
Orlistat—PNLIP—adipose tissue—breast cancer	0.00119	0.0184	CbGeAlD
Orlistat—PLA2G7—bone marrow—breast cancer	0.00118	0.0182	CbGeAlD
Orlistat—PLA2G7—female gonad—breast cancer	0.00114	0.0175	CbGeAlD
Orlistat—ABHD16A—bone marrow—breast cancer	0.00111	0.017	CbGeAlD
Orlistat—PNLIP—female reproductive system—breast cancer	0.0011	0.0169	CbGeAlD
Orlistat—ABHD12—adrenal gland—breast cancer	0.00107	0.0165	CbGeAlD
Orlistat—ABHD16A—female gonad—breast cancer	0.00107	0.0164	CbGeAlD
Orlistat—PLA2G7—endocrine gland—breast cancer	0.00106	0.0163	CbGeAlD
Orlistat—FASN—uterus—breast cancer	0.00102	0.0158	CbGeAlD
Orlistat—FASN—pituitary gland—breast cancer	0.00101	0.0155	CbGeAlD
Orlistat—FASN—adipose tissue—breast cancer	0.001	0.0154	CbGeAlD
Orlistat—PNLIP—female gonad—breast cancer	0.000999	0.0154	CbGeAlD
Orlistat—ABHD12—female gonad—breast cancer	0.000999	0.0154	CbGeAlD
Orlistat—PLA2G4A—Estradiol—Fulvestrant—breast cancer	0.000976	0.448	CbGdCrCtD
Orlistat—PNLIP—endocrine gland—breast cancer	0.000929	0.0143	CbGeAlD
Orlistat—DAGLB—lymph node—breast cancer	0.000904	0.0139	CbGeAlD
Orlistat—FASN—adrenal gland—breast cancer	0.000899	0.0139	CbGeAlD
Orlistat—PLA2G4A—nipple—breast cancer	0.000885	0.0136	CbGeAlD
Orlistat—FASN—female gonad—breast cancer	0.000838	0.0129	CbGeAlD
Orlistat—PLA2G7—lymph node—breast cancer	0.00073	0.0113	CbGeAlD
Orlistat—ABHD16A—lymph node—breast cancer	0.000685	0.0106	CbGeAlD
Orlistat—ABHD12—lymph node—breast cancer	0.000642	0.0099	CbGeAlD
Orlistat—PLA2G4A—Raltitrexed—Methotrexate—breast cancer	0.000584	0.268	CbGdCrCtD
Orlistat—FASN—lymph node—breast cancer	0.000539	0.0083	CbGeAlD
Orlistat—PLA2G4A—endometrium—breast cancer	0.000535	0.00824	CbGeAlD
Orlistat—PLA2G4A—pituitary gland—breast cancer	0.000484	0.00745	CbGeAlD
Orlistat—PLA2G4A—adipose tissue—breast cancer	0.000482	0.00742	CbGeAlD
Orlistat—PLA2G4A—female reproductive system—breast cancer	0.000443	0.00682	CbGeAlD
Orlistat—PLA2G4A—adrenal gland—breast cancer	0.000432	0.00666	CbGeAlD
Orlistat—PLA2G4A—bone marrow—breast cancer	0.000418	0.00644	CbGeAlD
Orlistat—PLA2G4A—female gonad—breast cancer	0.000403	0.00621	CbGeAlD
Orlistat—PLA2G4A—endocrine gland—breast cancer	0.000375	0.00577	CbGeAlD
Orlistat—FASN—Azacitidine—Gemcitabine—breast cancer	0.00034	0.156	CbGdCrCtD
Orlistat—PLA2G4A—lymph node—breast cancer	0.000259	0.00399	CbGeAlD
Orlistat—CYP3A4—female reproductive system—breast cancer	0.000146	0.00225	CbGeAlD
Orlistat—PLA2G4A—Dexamethasone—Fluoxymesterone—breast cancer	0.000139	0.064	CbGdCrCtD
Orlistat—PLA2G4A—Betamethasone—Fluoxymesterone—breast cancer	0.000139	0.064	CbGdCrCtD
Orlistat—CYP3A4—endocrine gland—breast cancer	0.000124	0.0019	CbGeAlD
Orlistat—Infection—Capecitabine—breast cancer	3.24e-05	0.000242	CcSEcCtD
Orlistat—Neuropathy peripheral—Doxorubicin—breast cancer	3.23e-05	0.000241	CcSEcCtD
Orlistat—Dizziness—Irinotecan—breast cancer	3.22e-05	0.00024	CcSEcCtD
Orlistat—Haemoglobin—Epirubicin—breast cancer	3.21e-05	0.00024	CcSEcCtD
Orlistat—Urinary tract infection—Doxorubicin—breast cancer	3.2e-05	0.000239	CcSEcCtD
Orlistat—Nervous system disorder—Capecitabine—breast cancer	3.2e-05	0.000239	CcSEcCtD
Orlistat—Haemorrhage—Epirubicin—breast cancer	3.2e-05	0.000239	CcSEcCtD
Orlistat—Hepatitis—Epirubicin—breast cancer	3.2e-05	0.000239	CcSEcCtD
Orlistat—Diarrhoea—Fluorouracil—breast cancer	3.19e-05	0.000238	CcSEcCtD
Orlistat—Pharyngitis—Epirubicin—breast cancer	3.17e-05	0.000237	CcSEcCtD
Orlistat—Skin disorder—Capecitabine—breast cancer	3.17e-05	0.000236	CcSEcCtD
Orlistat—Urinary tract disorder—Epirubicin—breast cancer	3.16e-05	0.000236	CcSEcCtD
Orlistat—Urticaria—Paclitaxel—breast cancer	3.16e-05	0.000236	CcSEcCtD
Orlistat—Hyperhidrosis—Capecitabine—breast cancer	3.15e-05	0.000235	CcSEcCtD
Orlistat—Oedema peripheral—Epirubicin—breast cancer	3.15e-05	0.000235	CcSEcCtD
Orlistat—Abdominal pain—Paclitaxel—breast cancer	3.14e-05	0.000234	CcSEcCtD
Orlistat—Body temperature increased—Paclitaxel—breast cancer	3.14e-05	0.000234	CcSEcCtD
Orlistat—Urethral disorder—Epirubicin—breast cancer	3.13e-05	0.000234	CcSEcCtD
Orlistat—Hepatobiliary disease—Doxorubicin—breast cancer	3.12e-05	0.000233	CcSEcCtD
Orlistat—Vomiting—Mitoxantrone—breast cancer	3.1e-05	0.000231	CcSEcCtD
Orlistat—Vomiting—Irinotecan—breast cancer	3.1e-05	0.000231	CcSEcCtD
Orlistat—Sinusitis—Doxorubicin—breast cancer	3.09e-05	0.000231	CcSEcCtD
Orlistat—Immune system disorder—Methotrexate—breast cancer	3.09e-05	0.00023	CcSEcCtD
Orlistat—Dizziness—Fluorouracil—breast cancer	3.09e-05	0.00023	CcSEcCtD
Orlistat—Mediastinal disorder—Methotrexate—breast cancer	3.08e-05	0.00023	CcSEcCtD
Orlistat—Rash—Mitoxantrone—breast cancer	3.07e-05	0.000229	CcSEcCtD
Orlistat—Rash—Irinotecan—breast cancer	3.07e-05	0.000229	CcSEcCtD
Orlistat—Dermatitis—Irinotecan—breast cancer	3.07e-05	0.000229	CcSEcCtD
Orlistat—Dermatitis—Mitoxantrone—breast cancer	3.07e-05	0.000229	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Docetaxel—breast cancer	3.07e-05	0.000229	CcSEcCtD
Orlistat—Headache—Mitoxantrone—breast cancer	3.05e-05	0.000228	CcSEcCtD
Orlistat—Headache—Irinotecan—breast cancer	3.05e-05	0.000228	CcSEcCtD
Orlistat—Insomnia—Docetaxel—breast cancer	3.05e-05	0.000227	CcSEcCtD
Orlistat—Paraesthesia—Docetaxel—breast cancer	3.02e-05	0.000226	CcSEcCtD
Orlistat—Alopecia—Methotrexate—breast cancer	3.02e-05	0.000225	CcSEcCtD
Orlistat—Vomiting—Gemcitabine—breast cancer	3.02e-05	0.000225	CcSEcCtD
Orlistat—Mental disorder—Methotrexate—breast cancer	2.99e-05	0.000223	CcSEcCtD
Orlistat—Rash—Gemcitabine—breast cancer	2.99e-05	0.000223	CcSEcCtD
Orlistat—Dermatitis—Gemcitabine—breast cancer	2.99e-05	0.000223	CcSEcCtD
Orlistat—Malnutrition—Methotrexate—breast cancer	2.97e-05	0.000222	CcSEcCtD
Orlistat—Haemoglobin—Doxorubicin—breast cancer	2.97e-05	0.000222	CcSEcCtD
Orlistat—Headache—Gemcitabine—breast cancer	2.97e-05	0.000222	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Capecitabine—breast cancer	2.97e-05	0.000222	CcSEcCtD
Orlistat—Vomiting—Fluorouracil—breast cancer	2.97e-05	0.000221	CcSEcCtD
Orlistat—Dyspepsia—Docetaxel—breast cancer	2.96e-05	0.000221	CcSEcCtD
Orlistat—Haemorrhage—Doxorubicin—breast cancer	2.96e-05	0.000221	CcSEcCtD
Orlistat—Hepatitis—Doxorubicin—breast cancer	2.96e-05	0.000221	CcSEcCtD
Orlistat—Insomnia—Capecitabine—breast cancer	2.95e-05	0.00022	CcSEcCtD
Orlistat—Rash—Fluorouracil—breast cancer	2.94e-05	0.00022	CcSEcCtD
Orlistat—Dermatitis—Fluorouracil—breast cancer	2.94e-05	0.000219	CcSEcCtD
Orlistat—Pharyngitis—Doxorubicin—breast cancer	2.94e-05	0.000219	CcSEcCtD
Orlistat—Paraesthesia—Capecitabine—breast cancer	2.93e-05	0.000218	CcSEcCtD
Orlistat—Decreased appetite—Docetaxel—breast cancer	2.93e-05	0.000218	CcSEcCtD
Orlistat—Hypersensitivity—Paclitaxel—breast cancer	2.93e-05	0.000218	CcSEcCtD
Orlistat—Headache—Fluorouracil—breast cancer	2.92e-05	0.000218	CcSEcCtD
Orlistat—Urinary tract disorder—Doxorubicin—breast cancer	2.92e-05	0.000218	CcSEcCtD
Orlistat—Oedema peripheral—Doxorubicin—breast cancer	2.91e-05	0.000217	CcSEcCtD
Orlistat—Dysgeusia—Methotrexate—breast cancer	2.91e-05	0.000217	CcSEcCtD
Orlistat—Gastrointestinal disorder—Docetaxel—breast cancer	2.91e-05	0.000217	CcSEcCtD
Orlistat—Fatigue—Docetaxel—breast cancer	2.9e-05	0.000217	CcSEcCtD
Orlistat—Urethral disorder—Doxorubicin—breast cancer	2.9e-05	0.000216	CcSEcCtD
Orlistat—Nausea—Mitoxantrone—breast cancer	2.89e-05	0.000216	CcSEcCtD
Orlistat—Nausea—Irinotecan—breast cancer	2.89e-05	0.000216	CcSEcCtD
Orlistat—Immune system disorder—Epirubicin—breast cancer	2.89e-05	0.000215	CcSEcCtD
Orlistat—Mediastinal disorder—Epirubicin—breast cancer	2.88e-05	0.000215	CcSEcCtD
Orlistat—Pain—Docetaxel—breast cancer	2.88e-05	0.000215	CcSEcCtD
Orlistat—Back pain—Methotrexate—breast cancer	2.88e-05	0.000215	CcSEcCtD
Orlistat—Dyspepsia—Capecitabine—breast cancer	2.87e-05	0.000214	CcSEcCtD
Orlistat—Asthenia—Paclitaxel—breast cancer	2.85e-05	0.000213	CcSEcCtD
Orlistat—Decreased appetite—Capecitabine—breast cancer	2.83e-05	0.000211	CcSEcCtD
Orlistat—Alopecia—Epirubicin—breast cancer	2.83e-05	0.000211	CcSEcCtD
Orlistat—Nausea—Gemcitabine—breast cancer	2.82e-05	0.00021	CcSEcCtD
Orlistat—Gastrointestinal disorder—Capecitabine—breast cancer	2.81e-05	0.00021	CcSEcCtD
Orlistat—Fatigue—Capecitabine—breast cancer	2.81e-05	0.00021	CcSEcCtD
Orlistat—Pruritus—Paclitaxel—breast cancer	2.81e-05	0.00021	CcSEcCtD
Orlistat—Vision blurred—Methotrexate—breast cancer	2.8e-05	0.000209	CcSEcCtD
Orlistat—Mental disorder—Epirubicin—breast cancer	2.8e-05	0.000209	CcSEcCtD
Orlistat—Pain—Capecitabine—breast cancer	2.79e-05	0.000208	CcSEcCtD
Orlistat—Malnutrition—Epirubicin—breast cancer	2.78e-05	0.000208	CcSEcCtD
Orlistat—Feeling abnormal—Docetaxel—breast cancer	2.78e-05	0.000207	CcSEcCtD
Orlistat—Nausea—Fluorouracil—breast cancer	2.77e-05	0.000207	CcSEcCtD
Orlistat—Ill-defined disorder—Methotrexate—breast cancer	2.76e-05	0.000206	CcSEcCtD
Orlistat—Gastrointestinal pain—Docetaxel—breast cancer	2.75e-05	0.000205	CcSEcCtD
Orlistat—Flatulence—Epirubicin—breast cancer	2.74e-05	0.000205	CcSEcCtD
Orlistat—Dysgeusia—Epirubicin—breast cancer	2.73e-05	0.000203	CcSEcCtD
Orlistat—Diarrhoea—Paclitaxel—breast cancer	2.72e-05	0.000203	CcSEcCtD
Orlistat—Back pain—Epirubicin—breast cancer	2.69e-05	0.000201	CcSEcCtD
Orlistat—Feeling abnormal—Capecitabine—breast cancer	2.69e-05	0.0002	CcSEcCtD
Orlistat—Malaise—Methotrexate—breast cancer	2.68e-05	0.0002	CcSEcCtD
Orlistat—Muscle spasms—Epirubicin—breast cancer	2.68e-05	0.0002	CcSEcCtD
Orlistat—Immune system disorder—Doxorubicin—breast cancer	2.67e-05	0.000199	CcSEcCtD
Orlistat—Vertigo—Methotrexate—breast cancer	2.67e-05	0.000199	CcSEcCtD
Orlistat—Gastrointestinal pain—Capecitabine—breast cancer	2.67e-05	0.000199	CcSEcCtD
Orlistat—Mediastinal disorder—Doxorubicin—breast cancer	2.67e-05	0.000199	CcSEcCtD
Orlistat—Abdominal pain—Docetaxel—breast cancer	2.66e-05	0.000199	CcSEcCtD
Orlistat—Body temperature increased—Docetaxel—breast cancer	2.66e-05	0.000199	CcSEcCtD
Orlistat—Dizziness—Paclitaxel—breast cancer	2.63e-05	0.000196	CcSEcCtD
Orlistat—Vision blurred—Epirubicin—breast cancer	2.62e-05	0.000196	CcSEcCtD
Orlistat—Alopecia—Doxorubicin—breast cancer	2.61e-05	0.000195	CcSEcCtD
Orlistat—Cough—Methotrexate—breast cancer	2.6e-05	0.000194	CcSEcCtD
Orlistat—Mental disorder—Doxorubicin—breast cancer	2.59e-05	0.000193	CcSEcCtD
Orlistat—Urticaria—Capecitabine—breast cancer	2.59e-05	0.000193	CcSEcCtD
Orlistat—Ill-defined disorder—Epirubicin—breast cancer	2.58e-05	0.000193	CcSEcCtD
Orlistat—Body temperature increased—Capecitabine—breast cancer	2.58e-05	0.000192	CcSEcCtD
Orlistat—Abdominal pain—Capecitabine—breast cancer	2.58e-05	0.000192	CcSEcCtD
Orlistat—Convulsion—Methotrexate—breast cancer	2.58e-05	0.000192	CcSEcCtD
Orlistat—Malnutrition—Doxorubicin—breast cancer	2.58e-05	0.000192	CcSEcCtD
Orlistat—Flatulence—Doxorubicin—breast cancer	2.54e-05	0.000189	CcSEcCtD
Orlistat—Chest pain—Methotrexate—breast cancer	2.53e-05	0.000189	CcSEcCtD
Orlistat—Myalgia—Methotrexate—breast cancer	2.53e-05	0.000189	CcSEcCtD
Orlistat—Vomiting—Paclitaxel—breast cancer	2.53e-05	0.000188	CcSEcCtD
Orlistat—Dysgeusia—Doxorubicin—breast cancer	2.52e-05	0.000188	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	2.51e-05	0.000188	CcSEcCtD
Orlistat—Malaise—Epirubicin—breast cancer	2.51e-05	0.000187	CcSEcCtD
Orlistat—Rash—Paclitaxel—breast cancer	2.51e-05	0.000187	CcSEcCtD
Orlistat—Dermatitis—Paclitaxel—breast cancer	2.5e-05	0.000187	CcSEcCtD
Orlistat—Discomfort—Methotrexate—breast cancer	2.5e-05	0.000187	CcSEcCtD
Orlistat—Vertigo—Epirubicin—breast cancer	2.5e-05	0.000187	CcSEcCtD
Orlistat—Back pain—Doxorubicin—breast cancer	2.49e-05	0.000186	CcSEcCtD
Orlistat—Headache—Paclitaxel—breast cancer	2.49e-05	0.000186	CcSEcCtD
Orlistat—Hypersensitivity—Docetaxel—breast cancer	2.48e-05	0.000185	CcSEcCtD
Orlistat—Muscle spasms—Doxorubicin—breast cancer	2.48e-05	0.000185	CcSEcCtD
Orlistat—Palpitations—Epirubicin—breast cancer	2.46e-05	0.000184	CcSEcCtD
Orlistat—Cough—Epirubicin—breast cancer	2.43e-05	0.000181	CcSEcCtD
Orlistat—Anaphylactic shock—Methotrexate—breast cancer	2.43e-05	0.000181	CcSEcCtD
Orlistat—Vision blurred—Doxorubicin—breast cancer	2.43e-05	0.000181	CcSEcCtD
Orlistat—Asthenia—Docetaxel—breast cancer	2.42e-05	0.00018	CcSEcCtD
Orlistat—Convulsion—Epirubicin—breast cancer	2.41e-05	0.00018	CcSEcCtD
Orlistat—Infection—Methotrexate—breast cancer	2.41e-05	0.00018	CcSEcCtD
Orlistat—Hypersensitivity—Capecitabine—breast cancer	2.4e-05	0.000179	CcSEcCtD
Orlistat—Ill-defined disorder—Doxorubicin—breast cancer	2.39e-05	0.000178	CcSEcCtD
Orlistat—Pruritus—Docetaxel—breast cancer	2.38e-05	0.000178	CcSEcCtD
Orlistat—Nervous system disorder—Methotrexate—breast cancer	2.38e-05	0.000178	CcSEcCtD
Orlistat—Chest pain—Epirubicin—breast cancer	2.37e-05	0.000177	CcSEcCtD
Orlistat—Myalgia—Epirubicin—breast cancer	2.37e-05	0.000177	CcSEcCtD
Orlistat—Anxiety—Epirubicin—breast cancer	2.36e-05	0.000176	CcSEcCtD
Orlistat—Nausea—Paclitaxel—breast cancer	2.36e-05	0.000176	CcSEcCtD
Orlistat—Skin disorder—Methotrexate—breast cancer	2.36e-05	0.000176	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	2.35e-05	0.000176	CcSEcCtD
Orlistat—Hyperhidrosis—Methotrexate—breast cancer	2.35e-05	0.000175	CcSEcCtD
Orlistat—Discomfort—Epirubicin—breast cancer	2.34e-05	0.000175	CcSEcCtD
Orlistat—Asthenia—Capecitabine—breast cancer	2.34e-05	0.000175	CcSEcCtD
Orlistat—Malaise—Doxorubicin—breast cancer	2.32e-05	0.000173	CcSEcCtD
Orlistat—Dry mouth—Epirubicin—breast cancer	2.32e-05	0.000173	CcSEcCtD
Orlistat—Vertigo—Doxorubicin—breast cancer	2.31e-05	0.000173	CcSEcCtD
Orlistat—Pruritus—Capecitabine—breast cancer	2.31e-05	0.000172	CcSEcCtD
Orlistat—Diarrhoea—Docetaxel—breast cancer	2.3e-05	0.000172	CcSEcCtD
Orlistat—Palpitations—Doxorubicin—breast cancer	2.28e-05	0.00017	CcSEcCtD
Orlistat—Oedema—Epirubicin—breast cancer	2.27e-05	0.000169	CcSEcCtD
Orlistat—Anaphylactic shock—Epirubicin—breast cancer	2.27e-05	0.000169	CcSEcCtD
Orlistat—Infection—Epirubicin—breast cancer	2.26e-05	0.000168	CcSEcCtD
Orlistat—Cough—Doxorubicin—breast cancer	2.25e-05	0.000168	CcSEcCtD
Orlistat—Convulsion—Doxorubicin—breast cancer	2.23e-05	0.000166	CcSEcCtD
Orlistat—Diarrhoea—Capecitabine—breast cancer	2.23e-05	0.000166	CcSEcCtD
Orlistat—Nervous system disorder—Epirubicin—breast cancer	2.23e-05	0.000166	CcSEcCtD
Orlistat—Dizziness—Docetaxel—breast cancer	2.23e-05	0.000166	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Methotrexate—breast cancer	2.21e-05	0.000165	CcSEcCtD
Orlistat—Skin disorder—Epirubicin—breast cancer	2.21e-05	0.000165	CcSEcCtD
Orlistat—Hyperhidrosis—Epirubicin—breast cancer	2.2e-05	0.000164	CcSEcCtD
Orlistat—Insomnia—Methotrexate—breast cancer	2.2e-05	0.000164	CcSEcCtD
Orlistat—Chest pain—Doxorubicin—breast cancer	2.19e-05	0.000164	CcSEcCtD
Orlistat—Myalgia—Doxorubicin—breast cancer	2.19e-05	0.000164	CcSEcCtD
Orlistat—Anxiety—Doxorubicin—breast cancer	2.18e-05	0.000163	CcSEcCtD
Orlistat—Paraesthesia—Methotrexate—breast cancer	2.18e-05	0.000163	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	2.18e-05	0.000162	CcSEcCtD
Orlistat—Discomfort—Doxorubicin—breast cancer	2.17e-05	0.000162	CcSEcCtD
Orlistat—Dizziness—Capecitabine—breast cancer	2.16e-05	0.000161	CcSEcCtD
Orlistat—Dry mouth—Doxorubicin—breast cancer	2.14e-05	0.00016	CcSEcCtD
Orlistat—Vomiting—Docetaxel—breast cancer	2.14e-05	0.00016	CcSEcCtD
Orlistat—Dyspepsia—Methotrexate—breast cancer	2.14e-05	0.000159	CcSEcCtD
Orlistat—Rash—Docetaxel—breast cancer	2.12e-05	0.000158	CcSEcCtD
Orlistat—Dermatitis—Docetaxel—breast cancer	2.12e-05	0.000158	CcSEcCtD
Orlistat—Decreased appetite—Methotrexate—breast cancer	2.11e-05	0.000157	CcSEcCtD
Orlistat—Headache—Docetaxel—breast cancer	2.11e-05	0.000157	CcSEcCtD
Orlistat—Anaphylactic shock—Doxorubicin—breast cancer	2.1e-05	0.000157	CcSEcCtD
Orlistat—Oedema—Doxorubicin—breast cancer	2.1e-05	0.000157	CcSEcCtD
Orlistat—Gastrointestinal disorder—Methotrexate—breast cancer	2.1e-05	0.000156	CcSEcCtD
Orlistat—Fatigue—Methotrexate—breast cancer	2.09e-05	0.000156	CcSEcCtD
Orlistat—Infection—Doxorubicin—breast cancer	2.09e-05	0.000156	CcSEcCtD
Orlistat—Pain—Methotrexate—breast cancer	2.08e-05	0.000155	CcSEcCtD
Orlistat—Vomiting—Capecitabine—breast cancer	2.07e-05	0.000155	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Epirubicin—breast cancer	2.07e-05	0.000154	CcSEcCtD
Orlistat—Nervous system disorder—Doxorubicin—breast cancer	2.06e-05	0.000154	CcSEcCtD
Orlistat—Rash—Capecitabine—breast cancer	2.06e-05	0.000153	CcSEcCtD
Orlistat—Insomnia—Epirubicin—breast cancer	2.05e-05	0.000153	CcSEcCtD
Orlistat—Dermatitis—Capecitabine—breast cancer	2.05e-05	0.000153	CcSEcCtD
Orlistat—Headache—Capecitabine—breast cancer	2.04e-05	0.000152	CcSEcCtD
Orlistat—Skin disorder—Doxorubicin—breast cancer	2.04e-05	0.000152	CcSEcCtD
Orlistat—Paraesthesia—Epirubicin—breast cancer	2.04e-05	0.000152	CcSEcCtD
Orlistat—Hyperhidrosis—Doxorubicin—breast cancer	2.03e-05	0.000152	CcSEcCtD
Orlistat—Nausea—Docetaxel—breast cancer	2e-05	0.000149	CcSEcCtD
Orlistat—Feeling abnormal—Methotrexate—breast cancer	2e-05	0.000149	CcSEcCtD
Orlistat—Dyspepsia—Epirubicin—breast cancer	2e-05	0.000149	CcSEcCtD
Orlistat—Gastrointestinal pain—Methotrexate—breast cancer	1.98e-05	0.000148	CcSEcCtD
Orlistat—Decreased appetite—Epirubicin—breast cancer	1.97e-05	0.000147	CcSEcCtD
Orlistat—Gastrointestinal disorder—Epirubicin—breast cancer	1.96e-05	0.000146	CcSEcCtD
Orlistat—Fatigue—Epirubicin—breast cancer	1.96e-05	0.000146	CcSEcCtD
Orlistat—Pain—Epirubicin—breast cancer	1.94e-05	0.000145	CcSEcCtD
Orlistat—Nausea—Capecitabine—breast cancer	1.94e-05	0.000145	CcSEcCtD
Orlistat—Urticaria—Methotrexate—breast cancer	1.93e-05	0.000144	CcSEcCtD
Orlistat—Abdominal pain—Methotrexate—breast cancer	1.92e-05	0.000143	CcSEcCtD
Orlistat—Body temperature increased—Methotrexate—breast cancer	1.92e-05	0.000143	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Doxorubicin—breast cancer	1.91e-05	0.000143	CcSEcCtD
Orlistat—Insomnia—Doxorubicin—breast cancer	1.9e-05	0.000142	CcSEcCtD
Orlistat—Paraesthesia—Doxorubicin—breast cancer	1.89e-05	0.000141	CcSEcCtD
Orlistat—Feeling abnormal—Epirubicin—breast cancer	1.87e-05	0.00014	CcSEcCtD
Orlistat—Gastrointestinal pain—Epirubicin—breast cancer	1.86e-05	0.000139	CcSEcCtD
Orlistat—Dyspepsia—Doxorubicin—breast cancer	1.85e-05	0.000138	CcSEcCtD
Orlistat—Decreased appetite—Doxorubicin—breast cancer	1.83e-05	0.000136	CcSEcCtD
Orlistat—Gastrointestinal disorder—Doxorubicin—breast cancer	1.81e-05	0.000135	CcSEcCtD
Orlistat—Fatigue—Doxorubicin—breast cancer	1.81e-05	0.000135	CcSEcCtD
Orlistat—Urticaria—Epirubicin—breast cancer	1.8e-05	0.000135	CcSEcCtD
Orlistat—Pain—Doxorubicin—breast cancer	1.8e-05	0.000134	CcSEcCtD
Orlistat—Abdominal pain—Epirubicin—breast cancer	1.8e-05	0.000134	CcSEcCtD
Orlistat—Body temperature increased—Epirubicin—breast cancer	1.8e-05	0.000134	CcSEcCtD
Orlistat—Hypersensitivity—Methotrexate—breast cancer	1.79e-05	0.000133	CcSEcCtD
Orlistat—Asthenia—Methotrexate—breast cancer	1.74e-05	0.00013	CcSEcCtD
Orlistat—Feeling abnormal—Doxorubicin—breast cancer	1.73e-05	0.000129	CcSEcCtD
Orlistat—Gastrointestinal pain—Doxorubicin—breast cancer	1.72e-05	0.000128	CcSEcCtD
Orlistat—Pruritus—Methotrexate—breast cancer	1.72e-05	0.000128	CcSEcCtD
Orlistat—Hypersensitivity—Epirubicin—breast cancer	1.67e-05	0.000125	CcSEcCtD
Orlistat—Urticaria—Doxorubicin—breast cancer	1.67e-05	0.000125	CcSEcCtD
Orlistat—Abdominal pain—Doxorubicin—breast cancer	1.66e-05	0.000124	CcSEcCtD
Orlistat—Body temperature increased—Doxorubicin—breast cancer	1.66e-05	0.000124	CcSEcCtD
Orlistat—Diarrhoea—Methotrexate—breast cancer	1.66e-05	0.000124	CcSEcCtD
Orlistat—Asthenia—Epirubicin—breast cancer	1.63e-05	0.000122	CcSEcCtD
Orlistat—Pruritus—Epirubicin—breast cancer	1.61e-05	0.00012	CcSEcCtD
Orlistat—Dizziness—Methotrexate—breast cancer	1.61e-05	0.00012	CcSEcCtD
Orlistat—Diarrhoea—Epirubicin—breast cancer	1.55e-05	0.000116	CcSEcCtD
Orlistat—Hypersensitivity—Doxorubicin—breast cancer	1.55e-05	0.000116	CcSEcCtD
Orlistat—Vomiting—Methotrexate—breast cancer	1.54e-05	0.000115	CcSEcCtD
Orlistat—Rash—Methotrexate—breast cancer	1.53e-05	0.000114	CcSEcCtD
Orlistat—Dermatitis—Methotrexate—breast cancer	1.53e-05	0.000114	CcSEcCtD
Orlistat—Headache—Methotrexate—breast cancer	1.52e-05	0.000113	CcSEcCtD
Orlistat—Asthenia—Doxorubicin—breast cancer	1.51e-05	0.000113	CcSEcCtD
Orlistat—Dizziness—Epirubicin—breast cancer	1.5e-05	0.000112	CcSEcCtD
Orlistat—Pruritus—Doxorubicin—breast cancer	1.49e-05	0.000111	CcSEcCtD
Orlistat—Vomiting—Epirubicin—breast cancer	1.44e-05	0.000108	CcSEcCtD
Orlistat—Nausea—Methotrexate—breast cancer	1.44e-05	0.000108	CcSEcCtD
Orlistat—Diarrhoea—Doxorubicin—breast cancer	1.44e-05	0.000107	CcSEcCtD
Orlistat—Rash—Epirubicin—breast cancer	1.43e-05	0.000107	CcSEcCtD
Orlistat—Dermatitis—Epirubicin—breast cancer	1.43e-05	0.000107	CcSEcCtD
Orlistat—Headache—Epirubicin—breast cancer	1.42e-05	0.000106	CcSEcCtD
Orlistat—Dizziness—Doxorubicin—breast cancer	1.39e-05	0.000104	CcSEcCtD
Orlistat—Nausea—Epirubicin—breast cancer	1.35e-05	0.000101	CcSEcCtD
Orlistat—Vomiting—Doxorubicin—breast cancer	1.34e-05	9.97e-05	CcSEcCtD
Orlistat—Rash—Doxorubicin—breast cancer	1.33e-05	9.89e-05	CcSEcCtD
Orlistat—Dermatitis—Doxorubicin—breast cancer	1.32e-05	9.88e-05	CcSEcCtD
Orlistat—Headache—Doxorubicin—breast cancer	1.32e-05	9.82e-05	CcSEcCtD
Orlistat—Nausea—Doxorubicin—breast cancer	1.25e-05	9.31e-05	CcSEcCtD
Orlistat—PLA2G4A—Signaling Pathways—JAG1—breast cancer	5.33e-06	5.43e-05	CbGpPWpGaD
Orlistat—FASN—Metabolism—PTEN—breast cancer	5.32e-06	5.41e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NOTCH3—breast cancer	5.31e-06	5.4e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PARP1—breast cancer	5.31e-06	5.4e-05	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PIK3CA—breast cancer	5.31e-06	5.4e-05	CbGpPWpGaD
Orlistat—FASN—Disease—MYC—breast cancer	5.28e-06	5.37e-05	CbGpPWpGaD
Orlistat—FASN—Disease—TGFB1—breast cancer	5.27e-06	5.36e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CALCA—breast cancer	5.25e-06	5.34e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MYC—breast cancer	5.23e-06	5.32e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—SRC—breast cancer	5.22e-06	5.31e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TGFB1—breast cancer	5.21e-06	5.3e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—RPS6—breast cancer	5.18e-06	5.27e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TP53—breast cancer	5.18e-06	5.27e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TP53—breast cancer	5.18e-06	5.27e-05	CbGpPWpGaD
Orlistat—PNLIP—Disease—AKT1—breast cancer	5.18e-06	5.26e-05	CbGpPWpGaD
Orlistat—FASN—Disease—EGFR—breast cancer	5.17e-06	5.25e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FGF4—breast cancer	5.14e-06	5.23e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PTEN—breast cancer	5.13e-06	5.22e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CXCL12—breast cancer	5.12e-06	5.21e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CXCR4—breast cancer	5.12e-06	5.21e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—EGFR—breast cancer	5.11e-06	5.2e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—VEGFA—breast cancer	5.09e-06	5.17e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—COMT—breast cancer	5.08e-06	5.17e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GSTP1—breast cancer	5.05e-06	5.14e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PAK1—breast cancer	5.03e-06	5.12e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—HMOX1—breast cancer	4.99e-06	5.07e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ITPR1—breast cancer	4.97e-06	5.06e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—HRAS—breast cancer	4.95e-06	5.04e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—HRAS—breast cancer	4.95e-06	5.04e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TCF7L2—breast cancer	4.94e-06	5.03e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PIK3CG—breast cancer	4.88e-06	4.97e-05	CbGpPWpGaD
Orlistat—FASN—Disease—KRAS—breast cancer	4.88e-06	4.96e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SYNJ2—breast cancer	4.85e-06	4.93e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—KRAS—breast cancer	4.83e-06	4.91e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—MAPK3—breast cancer	4.81e-06	4.9e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ABCB1—breast cancer	4.78e-06	4.87e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HSP90AA1—breast cancer	4.76e-06	4.85e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NOTCH2—breast cancer	4.76e-06	4.85e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IL6—breast cancer	4.74e-06	4.82e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IL6—breast cancer	4.74e-06	4.82e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—TYMS—breast cancer	4.7e-06	4.78e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—TGFB1—breast cancer	4.67e-06	4.75e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—NCOR1—breast cancer	4.64e-06	4.72e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GSTM1—breast cancer	4.64e-06	4.72e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AGTR1—breast cancer	4.63e-06	4.71e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PRL—breast cancer	4.63e-06	4.71e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—STK11—breast cancer	4.57e-06	4.65e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ADAM10—breast cancer	4.57e-06	4.65e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PLG—breast cancer	4.52e-06	4.59e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NDUFS3—breast cancer	4.51e-06	4.59e-05	CbGpPWpGaD
Orlistat—FASN—Disease—PIK3CA—breast cancer	4.48e-06	4.56e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—AKT2—breast cancer	4.47e-06	4.54e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GPX1—breast cancer	4.45e-06	4.52e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FGF10—breast cancer	4.44e-06	4.52e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PIK3CA—breast cancer	4.44e-06	4.51e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CYP1A1—breast cancer	4.4e-06	4.48e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—AKT1—breast cancer	4.37e-06	4.45e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—AKT1—breast cancer	4.37e-06	4.45e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ERCC2—breast cancer	4.37e-06	4.44e-05	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—AKT1—breast cancer	4.33e-06	4.41e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—KRAS—breast cancer	4.33e-06	4.4e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TP53—breast cancer	4.29e-06	4.37e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PIK3CD—breast cancer	4.29e-06	4.37e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PDGFA—breast cancer	4.29e-06	4.36e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CHST9—breast cancer	4.24e-06	4.31e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TGFBR2—breast cancer	4.23e-06	4.3e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ITPR1—breast cancer	4.16e-06	4.23e-05	CbGpPWpGaD
Orlistat—FASN—Disease—HRAS—breast cancer	4.15e-06	4.22e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MMP3—breast cancer	4.13e-06	4.2e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—STAT5A—breast cancer	4.13e-06	4.2e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ERBB4—breast cancer	4.13e-06	4.2e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—MTHFR—breast cancer	4.11e-06	4.18e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—HRAS—breast cancer	4.11e-06	4.18e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—COX11—breast cancer	4.02e-06	4.09e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SMAD4—breast cancer	4e-06	4.07e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IGF1R—breast cancer	3.98e-06	4.04e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—PIK3CA—breast cancer	3.97e-06	4.04e-05	CbGpPWpGaD
Orlistat—FASN—Disease—IL6—breast cancer	3.97e-06	4.04e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IL6—breast cancer	3.93e-06	4e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HES1—breast cancer	3.91e-06	3.97e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NCOR1—breast cancer	3.88e-06	3.95e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—TP53—breast cancer	3.84e-06	3.91e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FGF1—breast cancer	3.84e-06	3.91e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CSF2—breast cancer	3.84e-06	3.91e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—RAF1—breast cancer	3.83e-06	3.9e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NRG1—breast cancer	3.81e-06	3.88e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CAV1—breast cancer	3.79e-06	3.85e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—H2AFX—breast cancer	3.79e-06	3.85e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—E2F1—breast cancer	3.76e-06	3.82e-05	CbGpPWpGaD
Orlistat—FASN—Metabolism—PIK3CA—breast cancer	3.75e-06	3.82e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PIK3CB—breast cancer	3.74e-06	3.8e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SHMT1—breast cancer	3.68e-06	3.74e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CDA—breast cancer	3.68e-06	3.74e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—HRAS—breast cancer	3.68e-06	3.74e-05	CbGpPWpGaD
Orlistat—FASN—Disease—AKT1—breast cancer	3.66e-06	3.72e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—AKT1—breast cancer	3.62e-06	3.69e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	3.62e-06	3.68e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SPP1—breast cancer	3.61e-06	3.67e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CXCL8—breast cancer	3.59e-06	3.66e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ERBB3—breast cancer	3.57e-06	3.63e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FGFR2—breast cancer	3.57e-06	3.63e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SLCO1B1—breast cancer	3.54e-06	3.6e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SLC2A5—breast cancer	3.54e-06	3.6e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PIK3CG—breast cancer	3.45e-06	3.51e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—IL2—breast cancer	3.44e-06	3.49e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TERT—breast cancer	3.42e-06	3.48e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—APRT—breast cancer	3.42e-06	3.48e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FGFR1—breast cancer	3.32e-06	3.38e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HIF1A—breast cancer	3.27e-06	3.33e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—AKT1—breast cancer	3.25e-06	3.3e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ANGPTL4—breast cancer	3.21e-06	3.27e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ESRRA—breast cancer	3.21e-06	3.27e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—LEP—breast cancer	3.2e-06	3.25e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CAV1—breast cancer	3.17e-06	3.22e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—KDR—breast cancer	3.13e-06	3.18e-05	CbGpPWpGaD
Orlistat—FASN—Metabolism—AKT1—breast cancer	3.07e-06	3.12e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ESR1—breast cancer	3.05e-06	3.1e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GPI—breast cancer	3.05e-06	3.1e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HADHB—breast cancer	3.05e-06	3.1e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PIK3CD—breast cancer	3.03e-06	3.08e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FN1—breast cancer	3.01e-06	3.07e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ALB—breast cancer	2.99e-06	3.04e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NFKBIA—breast cancer	2.98e-06	3.03e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NOTCH1—breast cancer	2.95e-06	3e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ALDH1A1—breast cancer	2.91e-06	2.96e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ALDH7A1—breast cancer	2.91e-06	2.96e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—KIT—breast cancer	2.88e-06	2.93e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PIK3CG—breast cancer	2.88e-06	2.93e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—APC—breast cancer	2.88e-06	2.93e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—NOS3—breast cancer	2.86e-06	2.91e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—EGF—breast cancer	2.85e-06	2.9e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—FHL2—breast cancer	2.79e-06	2.83e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NME1—breast cancer	2.79e-06	2.83e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—UMPS—breast cancer	2.79e-06	2.83e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ADSL—breast cancer	2.79e-06	2.83e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PHGDH—breast cancer	2.79e-06	2.83e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—MAPK3—breast cancer	2.76e-06	2.81e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—BRIP1—breast cancer	2.73e-06	2.78e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—LDHB—breast cancer	2.73e-06	2.78e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HPSE—breast cancer	2.73e-06	2.78e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—BRAF—breast cancer	2.71e-06	2.76e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PIK3CB—breast cancer	2.64e-06	2.69e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IGF1—breast cancer	2.64e-06	2.69e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AKT2—breast cancer	2.64e-06	2.68e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—EGFR—breast cancer	2.63e-06	2.67e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PTGS2—breast cancer	2.62e-06	2.66e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HMMR—breast cancer	2.59e-06	2.63e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ABCC1—breast cancer	2.59e-06	2.63e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTA3—breast cancer	2.59e-06	2.63e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PIK3CD—breast cancer	2.54e-06	2.58e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PPARGC1B—breast cancer	2.51e-06	2.55e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SERPINE1—breast cancer	2.51e-06	2.55e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—KRAS—breast cancer	2.48e-06	2.52e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NOS3—breast cancer	2.39e-06	2.44e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTA4—breast cancer	2.37e-06	2.41e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CA9—breast cancer	2.37e-06	2.41e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTA2—breast cancer	2.31e-06	2.35e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GPX2—breast cancer	2.31e-06	2.35e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PTEN—breast cancer	2.28e-06	2.32e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SULT1A1—breast cancer	2.28e-06	2.32e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GPX4—breast cancer	2.28e-06	2.32e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PIK3CA—breast cancer	2.28e-06	2.32e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MDM2—breast cancer	2.27e-06	2.31e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—RAF1—breast cancer	2.26e-06	2.3e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—RELA—breast cancer	2.25e-06	2.29e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ERBB2—breast cancer	2.24e-06	2.28e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTA1—breast cancer	2.23e-06	2.27e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—IDH1—breast cancer	2.23e-06	2.27e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PIK3CB—breast cancer	2.21e-06	2.25e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MTOR—breast cancer	2.21e-06	2.25e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NAT2—breast cancer	2.2e-06	2.24e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CXCL8—breast cancer	2.12e-06	2.16e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—HRAS—breast cancer	2.11e-06	2.15e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CDKN1B—breast cancer	2.07e-06	2.11e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CASP3—breast cancer	2.03e-06	2.07e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IL2—breast cancer	2.03e-06	2.06e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—IL6—breast cancer	2.02e-06	2.05e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCND1—breast cancer	1.98e-06	2.01e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—JUN—breast cancer	1.97e-06	2.01e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CTNNB1—breast cancer	1.96e-06	1.99e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—DPYD—breast cancer	1.93e-06	1.96e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—MED12—breast cancer	1.93e-06	1.96e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MMP9—breast cancer	1.92e-06	1.95e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CDKN1A—breast cancer	1.91e-06	1.95e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PTEN—breast cancer	1.91e-06	1.94e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ALDOA—breast cancer	1.9e-06	1.93e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MAPK8—breast cancer	1.87e-06	1.9e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—AKT1—breast cancer	1.86e-06	1.89e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NCOA3—breast cancer	1.85e-06	1.88e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SLC2A2—breast cancer	1.83e-06	1.86e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CPT1A—breast cancer	1.8e-06	1.83e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—MTR—breast cancer	1.8e-06	1.83e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ABCG2—breast cancer	1.8e-06	1.83e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SRC—breast cancer	1.77e-06	1.8e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HPGDS—breast cancer	1.76e-06	1.79e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HBA1—breast cancer	1.75e-06	1.78e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—VEGFA—breast cancer	1.72e-06	1.75e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTT1—breast cancer	1.71e-06	1.74e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ACHE—breast cancer	1.71e-06	1.74e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—STAT3—breast cancer	1.71e-06	1.74e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MAPK3—breast cancer	1.63e-06	1.66e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP17A1—breast cancer	1.62e-06	1.64e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PIK3CA—breast cancer	1.61e-06	1.64e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ENO1—breast cancer	1.6e-06	1.63e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PTGS1—breast cancer	1.6e-06	1.63e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MYC—breast cancer	1.59e-06	1.61e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TGFB1—breast cancer	1.58e-06	1.61e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP2D6—breast cancer	1.57e-06	1.6e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—EGFR—breast cancer	1.55e-06	1.58e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NCOA2—breast cancer	1.54e-06	1.57e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—FASN—breast cancer	1.49e-06	1.52e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—BCHE—breast cancer	1.49e-06	1.51e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SLC5A5—breast cancer	1.47e-06	1.49e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—KRAS—breast cancer	1.47e-06	1.49e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NQO1—breast cancer	1.42e-06	1.44e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SLC2A1—breast cancer	1.42e-06	1.44e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP1B1—breast cancer	1.36e-06	1.38e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PIK3CA—breast cancer	1.35e-06	1.37e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HSP90AA1—breast cancer	1.33e-06	1.36e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—AKT1—breast cancer	1.32e-06	1.34e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TP53—breast cancer	1.3e-06	1.33e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NCOA1—breast cancer	1.3e-06	1.32e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP19A1—breast cancer	1.28e-06	1.3e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—STK11—breast cancer	1.28e-06	1.3e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HRAS—breast cancer	1.25e-06	1.27e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IL6—breast cancer	1.19e-06	1.21e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—COMT—breast cancer	1.19e-06	1.21e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTP1—breast cancer	1.18e-06	1.2e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HMOX1—breast cancer	1.17e-06	1.19e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ITPR1—breast cancer	1.16e-06	1.18e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ABCB1—breast cancer	1.12e-06	1.14e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—TYMS—breast cancer	1.1e-06	1.12e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AKT1—breast cancer	1.1e-06	1.12e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PLA2G4A—breast cancer	1.09e-06	1.11e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NCOR1—breast cancer	1.09e-06	1.11e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTM1—breast cancer	1.09e-06	1.11e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GPX1—breast cancer	1.04e-06	1.06e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP1A1—breast cancer	1.03e-06	1.05e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ERCC2—breast cancer	1.02e-06	1.04e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—MTHFR—breast cancer	9.61e-07	9.78e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CAV1—breast cancer	8.87e-07	9.02e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PIK3CG—breast cancer	8.08e-07	8.22e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PIK3CD—breast cancer	7.1e-07	7.22e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ALB—breast cancer	7.01e-07	7.13e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NOS3—breast cancer	6.71e-07	6.82e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PIK3CB—breast cancer	6.19e-07	6.3e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PTGS2—breast cancer	6.13e-07	6.24e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PTEN—breast cancer	5.35e-07	5.44e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PIK3CA—breast cancer	3.77e-07	3.84e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—AKT1—breast cancer	3.08e-07	3.14e-06	CbGpPWpGaD
